« Cell Genesys, Inc.’s GVAX® Immunotherapy Passed Follow-Up Phase 2 Clinical Trial for Pancreatic Cancer | Main | SQ109: Sequella, Inc.’s TB Drug Candidate, Received USFDA Fast Track Status »

Jan23
Bioponic Phytoceuticals’ Curecumin™ Product Potentially Effective Against Alzheimer's Disease (AD)

Curcumin, an active compound in turmeric, has been known for its anti-inflammatory and anti-oxidant properties. Researchers from UCLA/VA found that curcumin may help the immune system clear the brain of the amyloid beta plaques found in Alzheimer's disease patients.

curecumin_bottle.jpgThe findings have recently been published in the Journal of Alzheimer's Disease which may lead to a new approach in treating Alzheimer's disease by enhancing the natural function of the immune system using curcumin.

Bioponic Phytoceuticals, Inc. (OTC: BPYT) recently announced that its Curecumin™ product (a Bioresonant Phytotherapeutic™ form of Turmeric) may be an important treatment and/or preventative for Alzheimer's Disease.

According to Steven M. Schorr, Chairman & CEO of Bioponic Phytoceuticals, Inc.:

"We are particularly interested in the potential of our Curecumin™ nasal spray to deliver its benefits directly to the brain through the nasal cavity. If proven effective, we may have an efficacious, cost effective, natural treatment for the millions of Alzheimer's sufferers, and for those who seek to prevent the disease. With 75 million aging baby boomers the potential for this product is significant.”

Focusing on the production of natural products that are used to promote health and well-being, Bioponic Phytoceuticals is the developer, manufacturer and distributor of Bioresonant Phytotherapeutic™ products (a new healing modality) for sale in the Complementary Alternative Medicine ("CAM") and natural products markets.

Source: PR Newswire


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Cell Genesys, Inc.’s GVAX® Immunotherapy Passed Follow-Up Phase 2 Clinical Trial for Pancreatic Cancer | Main | SQ109: Sequella, Inc.’s TB Drug Candidate, Received USFDA Fast Track Status »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb